Navigation Links
Conn's, Caterpillar, Bristol-Myers Squibb, Novartis and AstraZeneca highlighted as Zacks Bull and Bear of the Day
Date:12/11/2013

Sprycel arm achieved an optimal molecular response at three months, compared to 64% in the Glivec arm. Moreover, the safety profile of Sprycel in the follow up study was found to be consistent with that observed earlier in Ph+ CP-CML patients.

 

Sprycel is one of the key drugs in Bristol-Myers' product portfolio. The drug performed impressively in the third quarter of 2013 with sales climbing 20% to $316 million. Apart from the long-term data on Sprycel, Bristol-Myers was in the news when the U.S. Food and Drug Administration (FDA) released the briefing documents ahead of the review by its Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the company's candidate metreleptin (proposed trade name: Myalept) on Dec 11,2013.

 

Bristol-Myers, which has an agreement with AstraZeneca (NYSE: AZN-Free Report) on the candidate, is looking to get it approved for treating metabolic disorders associated with lipodystrophy in pediatrics and adults suffering from the disease (not HIV related). Metreleptin has been granted priority review and a response from the FDA is expected by Feb 24, 2014. The content of the briefing documents highlighted that the candidate appeared to be beneficial only for a subgroup of patients. The candidate was not free from safety concerns as per the document. We believe investor focus will remain on updates regarding the candidate.

 

Bristol-Myers, a biopharmaceutical company, carries a Zacks Rank #3 (Hold).

 

Get today's Zacks #1 Stock of the Day with your free subscription to Profit from the Pros newsletter:

About the Bull and Bear of the Day

 

Every day, the analysts at Zacks Equity Research select two stocks that are likely t
'/>"/>

SOURCE Zacks Investment Research, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Financial Results, New Drug Applications, and Stock Price Movements - Research Report on Endo, Bristol-Myers Squibb, Express Scripts, AbbVie, and Incyte
2. Issuer Ratings, Recognitions, Positive Clinical Results, and Quarterly Dividends - Research Report on Pfizer, UnitedHealth, Merck, Gilead, and Bristol-Myers
3. Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China
4. Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
5. StockCall Insight into Eli Lilly, Bristol-Myers Squibb, Astex Pharmaceuticals and Raptor Pharmaceuticals
6. Life Technologies to Partner with Bristol-Myers Squibb for Companion Diagnostics Development
7. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
8. Amylin Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Bristol-Myers Squibb Company
9. Bristol-Myers Squibb to Present New Data on ORENCIA(R)? (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress
10. Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
11. 2013 ISPE Facility of the Year Awards Program Names Novartiss United States Flu Cell Culture Facility as Overall Winner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 On September 25 ... exhibition focusing on medical design and manufacturing - MEDTEC ... Shanghai World Expo Exhibition & Convention Center, bringing together ... and regions to showcase their latest medical-grade raw materials, ... only one week remaining for free visitor pre-registration to ...
(Date:9/16/2014)... , Sept. 16, 2014 The Lupus ... LLY ) today released results from UNVEIL: ... sheds light on the lupus journey and the challenges ... for lupus caregivers. The UNVEIL study, which involved over ... devastating impact lupus has on all aspects of life ...
(Date:9/16/2014)... Sept. 16, 2014  DNAtrix, Inc., experts in ... patient was treated with the company,s lead product, ... in a randomized, multicenter, open-label Phase Ib study ... in collaboration with leading neurosurgeons and neuro-oncologists in ... of our randomized Phase Ib study of DNX-2401 ...
Breaking Medicine Technology:MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2
... 3 out of 4 Patients in Cohort 2 Demonstrate T-Cell ... Potential ... Biopharmaceuticals,Corporation (TSX: NVN) today announced interim immunological data from the,first ... its lead product,candidate, HspE7, in patients with cervical intraepithelial neoplasia, ...
... 25, Astellas Pharma US, Inc. and its co-development,partner ... COM) announced the first,pivotal Phase III study evaluating ... today in Circulation,the official journal of the American ... the Atrial arrhythmia Conversion Trial (ACT I),the primary ...
Cached Medicine Technology:Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 3Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 4Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 5Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 6Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm 2Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm 3Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm 4Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm 5
(Date:9/16/2014)... 15, 2014 For patients with locally advanced pancreatic ... radiation (SABR) may be a promising treatment option, ... not otherwise be an option, according to research ... Oncology,s (ASTRO,s) 56th Annual Meeting. , Surgery is ... pancreatic ductal adenocarcinoma (PDA), the most common type ...
(Date:9/16/2014)... Texas (PRWEB) September 16, 2014 Beginning October ... adding a new service offering for its clients who book ... to the volume of business they buy. Most recurring ... during the work week, but others include clients whose ... pet sitter on a daily basis. The ...
(Date:9/16/2014)... Brightree® , the leading ... software solutions for the post-acute care industry, today ... of Brightree HME , serving home medical ... well as home infusion pharmacies. The release includes ... purchasing, document management and electronic eligibility checking all ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Synergy Research ... comprehensive report gives the best detail and analysis of ... pulled from a variety of sources, including Ministry of ... Orange Paper will give readers actionable intelligence on clinical ... Paper is relied on by the local and international ...
(Date:9/16/2014)... Valley Cellars and company owner Jay Rosen are featured ... This feature is part of the private cellars section ... company as a whole. , Washington Valley Cellars has ... wine storage solutions for their clients for over 15 ... across the country, especially in New York, New Jersey, ...
Breaking Medicine News(10 mins):Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 3Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 4Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 3Health News:Brightree Announces Availability of Latest Release 2Health News:Brightree Announces Availability of Latest Release 3Health News:Brightree Announces Availability of Latest Release 4Health News:Synergy Research Group Debuts Ukraine Orange Paper 2Health News:Washington Valley Cellars Featured in September Issue of Wine Spectator 2
... , ... Disease Foundation (VDF) is seeking nominations for the 2010 President’s Awards, which recognize those ... disease or have assisted the Foundation in accomplishing its mission in various categories. The ... ...
... ... this health observance day, VIP Smiles, owned by celebrity dentist Dr. Catrise Austin ... Street location by appointment from June 21st - June 28th, 2010. VIP Smiles ... offer the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test, which can be administered orally ...
... By combining two relatively inexpensive technologies based on sound and ... women undergo breast biopsies for suspicious lesions. Results of the ... edition and the August print issue of Radiology . ... the potential of diffuse optical tomography in the near infrared ...
... realize international health goals aiming to improve maternal health, ... is crucial. In an editorial published this week entitled ... editors argue that action on maternal health must ... much as it does access to basic medical care. ...
... appendages such as hair, nails, sweat glands and mammary ... the United States, according to a report in the ... of the JAMA/Archives journals. "Cutaneous appendageal carcinomas are ... diverse differentiation that frequently present a diagnostic challenge," the ...
... A new study in the journal Respirology ... acute exacerbations of chronic obstructive pulmonary disease (COPD) experience ... an increased risk of death, compared to those without ... due to impairment of immune responses. Researchers led by ...
Cached Medicine News:Health News:Nominations Wanted for Vascular Disease Foundation President's Awards 2Health News:June 27th Is National HIV Testing Day-New York Celebrity Dentist Offers Free Oral Rapid HIV Testing In the Dental Office 2Health News:June 27th Is National HIV Testing Day-New York Celebrity Dentist Offers Free Oral Rapid HIV Testing In the Dental Office 3Health News:Noninvasive combination technique may reduce number of breast biopsies 2Health News:Cancers of sweat glands, other skin-related structures may be increasing in United States 2
Nidek offers 3-Dx/F Digital stereo camera to provide a complete and comprehensive digital imaging platform....
Eye Q PRO is the optimum choice for ophthalmologists and clinicians specializing in advanced pathology and research....
Nidek LM-990A accomplishes precise measurement, quick response and easy operation....
... is a diversified wide-angle fundus ... ICG (optional) with various magnifications, ... the market), 40 degrees for ... picture and 30 degrees for ...
Medicine Products: